Desmoplastic Small Round Cell Tumor Treatment Market Report 2026

Desmoplastic Small Round Cell Tumor Treatment Market Overview

• Desmoplastic Small Round Cell Tumor Treatment market size has reached to $4.01 billion in 2025 • Expected to grow to $5.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Personalized Medicine Driving Growth In Desmoplastic Small Round Cell Tumor Treatment Market • North America was the largest region in 2025.

What Is Covered Under Desmoplastic Small Round Cell Tumor Treatment Market?

Desmoplastic small round cell tumor treatment encompasses various medical approaches, such as surgery, chemotherapy, and radiation therapy, designed to manage and control the progression of DSRCT, a rare and aggressive form of cancer. These treatments are used to target and limit the spread of cancerous cells, primarily in the abdominal area. The key benefit of DSRCT treatment is its potential to reduce tumor size, improve survival rates, and enhance the patient's overall quality of life. The main types in the desmoplastic small round cell tumor treatment market are immunotherapy, surgical operation, chemotherapy, and radiotherapy. Immunotherapy refers to a type of treatment that harnesses the body’s immune system to fight diseases, particularly cancer. The various drug classes include cytotoxic agents, targeted therapies, and immunomodulators, and several end users including hospitals, oncology clinics, and ambulatory surgical centers.

What Is The Desmoplastic Small Round Cell Tumor Treatment Market Growth Forecast?

The desmoplastic small round cell tumor treatment market size is expected to see strong growth in the next few years. It will grow to $5.92 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to development of targeted therapies and immunotherapies, integration of ai-driven diagnostics, rising clinical trials for dsrct, expansion of oncology clinics and ambulatory surgical centers, increasing healthcare funding for rare cancers. Major trends in the forecast period include rising adoption of multimodal cancer treatments, increasing focus on rare cancer research and clinical trials, growing investment in targeted therapies and immunotherapy, expansion of specialized oncology centers, enhanced patient support programs and post-treatment care.

Global Desmoplastic Small Round Cell Tumor Treatment Market Segmentation

1) By Type: Immunotherapy, Surgical Operation, Chemotherapy, Radiotherapy 2) By Drug Class: Cytotoxic Agents, Targeted Therapies, Immunomodulators 3) By End User: Hospitals, Oncology Clinics, Ambulatory Surgical Centers Subsegments: 1) By Immunotherapy: Checkpoint Inhibitors, CAR T-Cell Therapy, Monoclonal Antibodies, Immune Modulators 2) By Surgical Operation: Tumor Resection, Debulking Surgery, Laparoscopic Surgery 3) By Chemotherapy: Neoadjuvant Chemotherapy, Adjuvant Chemotherapy, Targeted Therapy Agents 4) By Radiotherapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Stereotactic Radiosurgery (SRS)

What Are The Drivers Of The Desmoplastic Small Round Cell Tumor Treatment Market?

The increased focus on personalized medicine is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Personalized medicine involves customizing healthcare based on a patient's unique genetic profile, lifestyle, and environment. It includes approaches such as pharmacogenomics, targeted therapies, and gene editing to provide more precise and effective treatments. The growing emphasis on personalized medicine is driven by advancements in genomics, improved patient outcomes, and the potential for more targeted and effective treatments. Personalized medicine helps in treating desmoplastic small round cell tumor (DSRCT) by tailoring therapies based on the tumor's specific genetic and molecular profile, enabling targeted treatments that improve efficacy and reduce side effects. For instance, in February 2024, Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the six approved in 2022. Therefore, increased focus on personalized medicine is driving the desmoplastic small round cell tumor treatment industry. Growing investment in oncology research is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Investment in oncology research is on the rise due to growing global cancer incidence, advancements in precision medicine, and the increasing need for innovative treatments and therapies to improve patient outcomes. Oncology research aids in the treatment of desmoplastic small round cell tumors by advancing understanding of the tumor's biology, leading to the development of targeted therapies and improved treatment protocols that enhance patient outcomes. For instance, in 2023, according to Office for National Statistics, a UK-based, government agency, the UK government’s net spending on research and development (R&D) increased to £17.4 ($22.1 billion) billion in 2023, up from £16.1 billion ($20.45 billion) in 2022, marking an 8.2% rise. Therefore, growing investment in oncology research is driving the desmoplastic small round cell tumor treatment industry. The rising number of clinical trials is expected to propel the growth of the desmoplastic small round cell tumor treatment market going forward. Clinical trials involve human volunteers and assess the safety and effectiveness of new medical treatments or procedures, aiming to gather scientific data on their suitability for human use. The rising number of clinical trials is primarily attributed to advancements in medical research, increased disease burden, regulatory changes, globalization of clinical research, patient advocacy and awareness, industry competition, technological advancements, and funding opportunities. Clinical trials provide access to innovative therapies and evaluating the effectiveness of new treatments, improving patient outcomes and advancing the development of targeted and more effective treatment options. For instance, in December 2025, according to the Association of the British Pharmaceutical Industry, a UK-based trade association, the number of new industry-sponsored trials initiated in the UK increased by 36% in 2024, rising to 578 trials from 426 in 2023. As a result, the UK moved up to sixth place globally for phase III trial starts in 2024, compared with eighth place in 2023. Therefore, the rising number of clinical trials is driving the growth of the desmoplastic small round cell tumor treatment industry.

Key Players In The Global Desmoplastic Small Round Cell Tumor Treatment Market

Major companies operating in the desmoplastic small round cell tumor treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Fresenius Kabi AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Zymeworks Inc., Blueprint Medicines Corporation, MacroGenics Inc., Exelixis Inc

Regional Outlook

North America was the largest region in the desmoplastic small round cell tumor treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Desmoplastic Small Round Cell Tumor Treatment Market?

The desmoplastic small round cell tumor treatment market includes revenues earned by entities by providing services such as immunotherapy, diagnostic imaging, and post treatment care, including rehabilitation and follow up monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.